When should drug treatment be started for people with dementia?

Maturitas

Volumn 62, Issue 3, 2009, Pages 230-234

  Singh, Baldev ^a   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Antidementia drugs; Cholinesterease inhibitors; Dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

COGNITIVE DEFECT; COMORBIDITY; DAILY LIFE ACTIVITY; DEMENTIA; HUMAN; MINI MENTAL STATE EXAMINATION; REVIEW; SOCIAL STATUS; VALIDATION PROCESS;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE;

EID: 62849099200     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.12.022     Document Type: Review

References (41)

1. WHO. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organisation; 1992.
2. APA. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Publishing Inc., Arlington, VA
3. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
4. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop [see comments]. Neurology 43 (1993) 250-260
5. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
6. Murray M.D., Lane K.A., Gao S., et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 162 (2002) 2090-2096
7. Forette F., Seux M.L., Staessen J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. [see comment] [erratum appears in Arch Intern Med. 2003 Jan 27;163(2):241.]. Arch Intern Med 162 (2002) 2046-2052
8. Clare L., Woods R.T., Moniz Cook E.D., Orrell M., and Spector A. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev (2003) CD003260
9. Spector A., Thorgrimsen L., Woods B., et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. [see comment]. Br J Psychiatry 183 (2003) 248-254
10. Woods B., Spector A., Jones C., Orrell M., and Davies S. Reminiscence therapy for dementia. [update of Cochrane Database Syst Rev. 2000;(4):CD001120]. Cochrane Database Syst Rev (2005) CD001120
11. Kavirajan H., and Schneider L.S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. [see comment]. Lancet Neurol 6 (2007) 782-792
12. McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
13. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. [see comment]. N Engl J Med 351 (2004) 2509-2518
14. Burns A., O'Brien J., and group BAPDC. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 20 (2006) 732-755
15. SIGN. Management of patients with dementia. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2006.
16. Waldemar G., Dubois B., Emre M., et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14 (2007) e1-26
17. APA. Practice Guideline for the treatment of patients with Alzheimer's disease and other dementias. Arlington VA: American Psychiatric Publishing Inc.; 2007.
18. NICE. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). NICE technology appraisal guidance. UK: National Institute for Health and Clinical Excellence; 2007.
19. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006) CD005593
20. Birks J., and Harvey R.J. Donepezil for dementia due to Alzheimer's disease. [update of Cochrane Database Syst Rev 2003;(3):CD001190]. Cochrane Database Syst Rev (2006) CD001190
21. Loy C., and Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. [update of Cochrane Database Syst Rev 2004;(4):CD001747]. Cochrane Database Syst Rev (2006) CD001747
22. Birks J., Grimley Evans J., Iakovidou V., and Tsolaki M. Rivastigmine for Alzheimer's disease. [update of Cochrane Database Syst Rev 2000;(2):CD001191]. Cochrane Database Syst Rev (2000) CD001191
23. Wilkinson D.G., Passmore A.P., Bullock R., et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 56 (2002) 441-446
24. Wilcock G., Howe I., Coles H., et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs & Aging 20 (2003) 777-789
25. McShane R., Areosa Sastre A., and Minakaran N. Memantine for dementia. [update of Cochrane Database Syst Rev 2005;(3):CD003154]. Cochrane Database Syst Rev (2006) CD003154
26. Courtney C., Farrell D., Gray R., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. [see comment]. Lancet 363 (2004) 2105-2115
27. Rockwood K., Black S.E., Robillard A., and Lussier I. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry 19 (2004) 954-960
28. Bains J., Birks J.S., and Dening T.R. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev (2002) CD003944
29. Ballard C., and Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (2006) CD003476
30. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. [see comment]. N Engl J Med 352 (2005) 2379-2388
31. Feldman H.H., Ferris S., Winblad B., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. [see comment] [erratum appears in Lancet Neurol 2007 Oct;6(10):849]. Lancet Neurol 6 (2007) 501-512
32. Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., and Pratt R.D. Donepezil Study G. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
33. Small G.W., Kaufer D., Mendiondo M.S., Quarg P., and Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract Suppl 59 (2005) 473-477
34. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res 34 (2006) 339-347
35. Rogers S.L., Doody R.S., Pratt R.D., and Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10 (2000) 195-203
36. Raskind M.A., Peskind E.R., Truyen L., Kershaw P., and Damaraju C.V. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61 (2004) 252-256
37. Farlow M., Anand R., Messina Jr. J., Hartman R., and Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44 (2000) 236-241
38. O'Brien J.T. NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom?. Lancet Neurol 5 (2006) 994-996
39. Purandare N., Ballard C., and Burns A. Preventing dementia. Adv Psychiatr Treat 11 (2005) 176-187
40. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. [see comment]. Nat Med 9 (2003) 448-452
41. Holmes C., Boche D., Wilkinson D., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. [see comment]. Lancet 372 (2008) 216-223